Characterization of a severe parenchymal phenotype of experimental autoimmune encephalomyelitis in (C57BL6xB10.PL)F1 mice

Journal of Neuroimmunology

Volumn 187, Issue 1-2, 2007, Pages 31-43

  Carrithers, Michael D ^a   Carrithers, Lisette M ^a   Czyzyk, Jan ^a   Henegariu, Octavian ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adoptive transfer; CD8 T cells; cDNA microarray; EAE MS

Indexed keywords

CD8 ANTIGEN; COMPLEMENTARY DNA;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DNA MICROARRAY; FLOW CYTOMETRY; GENE EXPRESSION; HISTOLOGY; INFLAMMATORY INFILTRATE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SPINAL CORD; T LYMPHOCYTE; WHITE MATTER;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD8; BRAIN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE EXPRESSION REGULATION; MACROPHAGE-1 ANTIGEN; MENINGES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYELIN BASIC PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPINAL CORD;

EID: 34347226291     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.04.007     Document Type: Article

References (43)

1. Babbe H., Roers A., Waisman A., Lassmann H., Goebels N., Hohlfeld R., Friese M., Schroder R., Deckert M., Schmidt S., Ravid R., and Rajewsky K. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192 (2000) 393-404
2. Baron J.L., Madri J.A., Ruddle N.H., Hashim G., and Janeway Jr. C.A. Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 177 (1993) 57-68
3. Berger J.R., and Koralnik I.J. Progressive multifocal leukoencephalopathy and natalizumab-unforeseen consequences. N. Engl. J. Med. 353 (2005) 414-416
4. Booss J., Esiri M., Tourtellotte W., and Mason D. Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J. Neurol. Sci. 62 (1983) 219-232
5. Brabb T., Von Dassow P., Ordonez N., Schnabel B., Duke B., and Goverman J. In situ tolerance within the central nervous system as a mechanism for preventing autoimmunity. J. Exp. Med. 192 (2000) 871-880
6. Carrithers M.D., Visintin I., and Janeway Jr. C.A. Dependence of cellular phenotype and genetic background on immune surveillance of the brain by T lymphocytes. J. Neuroimmunol. 129 (2002) 51-57
7. Carrithers M.D., Visintin I., Kang S.J., and Janeway Jr. C.A. Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment. Brain 123 (2000) 1092-1101
8. Cepok S., Jacobsen M., Schock S., Omer B., Jaekel S., Boddeker I., Oertel W.H., Sommer N., and Hemmer B. Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 124 (2001) 2169-2176
9. Chu C.Q., Wittmer S., and Dalton D.K. Failure to suppress the expansion of the activated CD4 T cell population in interferon γ-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis (EAE). J. Exp. Med. 192 (2000) 123-128
10. Engelhardt B., and Ransohoff R.M. The ins and outs of T lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 26 (2005) 485-495
11. Ferber I.A., Brocke S., Taylor-Edwards C., Ridgeway W., Dinisco C., Steinman L., Dalton D., and Fathman C.G. Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis. J. Immunol. 156 (1996) 5-7
12. Friese M.A., and Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy?. Brain 128 (2005) 1747-1763
13. Furlan R., Brambilla E., Ruffini F., Poliani P.L., Bergami A., Marconi P.C., Franciotta D.M., Penna G., Comi G., Adorini L., and Martino G. Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J. Immunol. 167 (2001) 1821-1829
14. Gold R., Linington C., and Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129 (2006) 1953-1971
15. Hickey W.F., Hsu B.L., and Kimura H. T-lymphocyte entry into the central nervous system. J. Neurosci. Res. 128 (1991) 254-260
16. Huseby E.S., Liggitt D., Brabb T., Schnabel B., Ohlen C., and Goverman J. A pathogenic role for myelin specific CD8(+) T cells in a model for multiple sclerosis. J. Exp. Med. 194 (2001) 669-676
17. Jacobsen M., Cepok S., Quak E., Happel M., Gaber R., Ziegler A., Schock S., Oertel W.H., Sommer N., and Hemmer B. Oligoclonal expansion of memory CD8(+) T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 125 (2002) 538-550
18. Jiang H., Braunstein N.S., Yu B., Winchester R., and Chess L. CD8(+) T cells control the TH phenotype of MBP-reactive CD4(+) T cells in EAE mice. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 6301-6306
19. Jiang H., Zhang S., and Pernis B. Role of CD8(+) T cells in murine experimental allergic encephalomyelitis. Science 5060 (1992) 1213-1215
20. Josephs K.A., Rubino F.A., and Dickson D.W. Nonvasculitic autoimmune inflammatory meningoencephalitis. Neuropathology 24 (2004) 149-152
21. Kamath A.T., Sheasby C.E., and Tough D.F. Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN αβ and IFN γ. J. Immunol. 174 (2005) 767-776
22. Keegan M., and Noseworthy J. Multiple sclerosis. Annu. Rev. Med. 53 (2002) 285-302
23. Kleinschmidt-DeMasters B.K., and Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. 353 (2005) 369-374
24. Koh D.R., Fung-Leung W.P., Ho A., Gray D., Acha-Orbea H., and Mak T.W. Less mortality but more relapses in experimental allergic encephalomyelitis in CD8 -/-mice. Science 5060 (1992) 1210-1213
25. Kuhlmann T., Lingfeld G., Bitsch A., Schuchardt J., and Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125 (2002) 2202-2212
26. Lafaille J.J., Nagashima K., Katsuki M., and Tonegawa S. High incidence of spontaneous autoimmune encephalomyelitis in immune deficient anti-myelin basic protein T cell receptor transgenic mice. Cell 78 (1994) 399-408
27. Langer-Gould A., Atlas S.W., Green A.J., Bollen A.W., and Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353 (2005) 375-381
28. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., and Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47 (2000) 707-717
29. McCallum K., Esiri M., Tourtellotte W., and Booss J. T cell subsets in multiple sclerosis. Gradients at plaque borders and differences in nonplaque regions. Brain 110 (1987) 1297-1308
30. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M., Wilmer A.J., Hulme C.M., Dalton K.A., Mizkiel P.W., O'Connor, and the International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. New Engl. J. Med. 348 (2003) 15-23
31. Panitch H.S., Hirsch R.L., Haley A.S., and Johnson K.P. Exacerbations of multiple sclerosis patients treated with gamma interferon. Lancet 18 (1987) 893-895
32. Sprent J. Turnover of memory-phenotype CD8 T cells. Microbes Infect. 5 (2003) 227-231
33. Sun D., Whitaker J.N., Huang Z., Liu D., Coleclough C., Wekerle H., and Raine C.S. Myelin antigen-specific CD8(+) T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J. Immunol. 166 (2001) 7579-7587
34. Thompson A.J., Polman C.H., Miller D.H., McDonald W.I., Brochet B., Filippi M., Montalban X., and De Sa J. Primary progressive multiple sclerosis. Brain 120 (1997) 1085-1096
35. Tough D.F., Sun S., and Sprent J. T cell stimulation in vivo by lipopolysaccharide. J. Exp. Med. 185 (1997) 2089-2094
36. Tran E.H., Prince E.N., and Owens T. IFN-γ shapes immune invasion of the central nervous system via regulation of chemokines. J. Immunol. 164 (2000) 2759-2768
37. Van Assche G., Van Ranst M., Sciot R., et al. Progressive multifocal leukoencephalopathy after natalizumab treatment for Crohn's disease. N. Engl. J. Med. 353 (2005) 362-368
38. Van Oosten B.W., Lai M., Hodkinson S., Barkhof F., Miller D.H., Moseley I.F., Thompson A.J., Rudge P., McDougall A., McLeod J.G., Adler H.J., and Polman C.H. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 49 (1997) 351-357
39. Weinshenker B.G. The natural history of multiple sclerosis. Neurol. Clin. 13 (1995) 119-146
40. Weinshenker B.G., Bass B., Rice G.P., Noseworthy J., Carriere W., Baskerville J., and Ebers G.C. The natural history of multiple sclerosis: a geographically based study. 2. Predicitve value of the early clinical course. Brain 112 (1989) 1419-1428
41. Wensky A.K., Furtado G.C., Garibaldi-Marconedes M.C., Chen S., Manfra D., Lifra S.A., Zagzag D., and Lafaille J.J. IFN-γ determines distinct clinical outcomes in autoimmune encephalomyelitis. J. Immunol. 174 (2005) 1416-1423
42. Willenborg D.O., Fordham S., Bernard C.C., Cowden W.B., and Ramshaw I.A. IFN-γ plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J. Immunol. 157 (1996) 3223-3227
43. Zamvil S., and Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 8 (1990) 579-621